CMPS earnings analysis
What we found in CMPS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Compass Pathways remains pre-revenue, with revenue of $0, and Q2 operating loss increased to $52.4 million from $42.9 million in the prior-year quarter as commercial-preparedness spending accelerated. The reported Q2 net loss surged to $253.8 million from $38.4 million, dominated by a $205.6 million non-cash warrant-liability revaluation loss; reported EPS was not included in the extracted filing text. Clinical and regulatory execution remains constructive following COMP006's p<0.001 primary-endpoint result and ongoing rolling NDA review, while $433.3 million of cash is expected to fund operations into 2028.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Phase 3 efficacy and NDA review progress
- COMP360's Phase 3 COMP006 trial met its primary endpoint: two 25 mg doses administered 3 weeks apart produced a -3.8-point difference in MADRS change at week 6 versus 1 mg, with p<0.001. FDA rolling NDA review is ongoing and the company received a National Priority Voucher in April 2026.
- Cash runway projected into 2028
- Cash and cash equivalents reached $433.3 million at June 30, 2026. Management believes this balance funds operations and capital expenditures into 2028.
- R&D expense declined as TRD program matures
- Q2 R&D expense declined $1.2 million year over year to $29.2 million from $30.3 million, primarily reflecting lower clinical-trial expense as the TRD Phase 3 program approaches completion.
- Operating cash burn broadly stable
- Operating cash use was $88.2 million for the first six months of 2026, only $3.9 million above $84.3 million in the prior-year period, despite expansion of commercial-preparedness activities.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Warrant revaluation sharply expanded GAAP loss
- The Q2 net loss widened to $253.8 million from $38.4 million a year earlier, chiefly due to a $205.6 million fair-value loss on warrant liabilities versus a $2.5 million loss in Q2 2025. This liability remeasurement can drive substantial quarterly earnings volatility independent of operations.
- No revenue and sustained funding requirement
- The company has generated $0 revenue and reported a $985.2 million accumulated deficit at June 30, 2026. Management expects expenses to rise for NDA work, manufacturing, commercialization preparation and the PTSD Phase 2b/3 program.
- Debt covenant creates 2027 liquidity risk
- Hercules debt covenants require specified minimum cash balances beginning October 1, 2027 unless market capitalization is at least $850.0 million over the stated 5-trading-day test period. The company says it will need additional financing or significantly lower operating expense to maintain compliance.
- Approval and DEA scheduling remain critical
- Commercial launch remains contingent on FDA approval and controlled-substance scheduling. While the National Priority Review pilot targets a decision within 1-2 months after a complete application is filed, the filing can be extended for an incomplete application, manufacturing issues, ambiguous pivotal data or other reasons.
- Outstanding warrants create dilution risk
- Potential shareholder dilution remains substantial: 23,848,829 pre-funded warrants were outstanding at June 30, 2026, and all outstanding warrants could result in issuance of 35,752,751 ADSs. Pre-funded warrant exercise provides only $0.0001 per ADS in cash.
- Commercial preparation is raising overhead
- Q2 general and administrative expense increased to $23.2 million from $12.6 million year over year, driven by commercial-preparedness staffing, consultants, technology and related costs. This partially offset the $1.2 million reduction in R&D expense.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management expects existing cash and cash equivalents of $433.3 million to fund operating expenses and capital expenditures into 2028, while stating it could require additional funding in the longer term.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Compass Pathways' Q1 2026 results show a net income of $91.2 million, significantly up from a net loss of $17.9 million a year earlier, primarily due to a fair value change of warrant liabilities. However, the company…
- 10-K · March 24, 2026
- Compass Pathways’ 2025 Form 10-K highlights material clinical de-risking: both Phase 3 pivotal TRD trials met their primary endpoints (COMP005 and COMP006) and the company is engaging the FDA on a rolling NDA…
- 10-Q · July 31, 2025
- Compass Pathways reported a Q2 net loss of $38,403 (EPS $(0.41)), roughly in line with the prior-year quarter's net loss of $38,101 though EPS improved versus comparable periods due to a larger share count. Cash and…
- 10-Q · May 8, 2025
- Compass Pathways reported a smaller net loss for Q1 2025: net loss of $(17,864) vs $(35,187) in Q1 2024, and diluted loss per share narrowed to $(0.24) from $(0.55). Cash increased materially to $260,110 (cash & cash…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CMPS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever